Xianwen Liu

Dr. Xianwen Liu

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Bone
Verified
Journal Article
Closed access
BHBingqiang Hua
Bingqiang Hua
JQJin Qiu
Jin Qiu
XYXiaoping Ye
Xiaoping Ye
XLXianwen Liu
Xianwen Liu

22 December 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
XYXiaoping Ye
Xiaoping Ye
XLXianwen Liu
Xianwen Liu
Wnts are secreted cysteine-rich glycoproteins involved in joint development and skeletal homeostasis and have been implicated in the occurrence of osteoarthritis. Over the past decade, Wnt16, a member of the Wnt family, has received widespread attention for its strong association with bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. In recent years, further studies have shed light on the role of Wnt16 a positive regulator of bone mass and protective regulator of osteoarthritis progression. Transduction mechanisms and crosstalk involving Wnt16 signaling have also been illustrated. More importantly, local Wnt16 treatment has been shown to ease osteoarthritis, inhibit bone resorption, and promote new bone formation in bone defect models. Thus, Wnt16 is now a potential therapeutic target for skeletal diseases and osteoarthritis. This paper reviews our current understanding of the mechanisms by which Wnt16 signaling regulates bone homeostasis and osteoarthritis.

11 July 2024 in Aging Cell
Verified
Journal Article
Open access
XYXiaoping Ye
Xiaoping Ye
XLXinping Li
Xinping Li
JQJin Qiu
Jin Qiu
YKYiwen Kuang
Yiwen Kuang
BHBingqiang Hua
Bingqiang Hua
XLXianwen Liu
Xianwen Liu
Recent studies have shed light on the important role of aging in the pathogenesis of joint degenerative diseases and the anti‐aging effect of alpha‐ketoglutarate (αKG). However, whether αKG has any effect on temporomandibular joint osteoarthritis (TMJOA) is unknown. Here, we demonstrate that αKG administration improves condylar cartilage health of middle‐aged/aged mice, and ameliorates pathological changes in a rat model of partial discectomy (PDE) induced TMJOA. In vitro, αKG reverses IL‐1β‐induced/H2O2‐induced decrease of chondrogenic markers (Col2, Acan and Sox9), and inhibited IL‐1β‐induced/ H2O2‐induced elevation of cartilage catabolic markers (ADAMTS5 and MMP13) in condylar chondrocytes. In addition, αKG downregulates senescence‐associated (SA) hallmarks of aged chondrocytes, including the mRNA/protein level of SA genes (p16 and p53), markers of nuclear disorders (Lamin A/C) and SA‐β‐gal activities. Mechanically, αKG decreases the expressions of p‐IKK and p‐NF‐κB, protecting TMJ from inflammation and senescence‐related damage by regulating the NF‐κB signaling. Collectively, our findings illuminate that αKG can ameliorate age‐related TMJOA and PDE‐induced TMJOA, maintain the homeostasis of cartilage matrix, and exert anti‐aging effects in chondrocytes, with a promising therapeutic potential in TMJOA, especially age‐related TMJOA.

16 July 2025 in Materials Today Bio
Verified
Journal Article
Open access
YKYiwen Kuang
Yiwen Kuang
BHBingqiang Hua
Bingqiang Hua
XYXiaoping Ye
Xiaoping Ye
YZYujin Zhao
Yujin Zhao
MYMeng Yu
Meng Yu
XLXianwen Liu
Xianwen Liu
Temporomandibular joint osteoarthritis (TMJOA) is a degenerative disease characterized by variable degrees of inflammatory cartilage degeneration and subchondral bone erosion. Current clinical treatments mainly focus on symptomatic relief, such as pain management, and no disease-modifying osteoarthritis (OA) drugs (DMOADs) have been approved for widespread clinical use by regulatory bodies. Although fibroblast growth factor (FGF18) has shown great potential to be DMOADs in clinical trials for OA treatment by stimulating cartilage regeneration, its efficacy of inducing anabolic responses in articular cartilage is significantly limited by inflammatory conditions. In this study, we delivered FGF18 using an innovative hydrogel that underwent responsive degradation in the reactive oxygen species (ROS)-enriched TMJOA sites, continuously delivering the cartilage-repairing FGF18 and consuming ROS, further counteracting the limitation of inflammatory factors on cartilage repair ability of FGF18, thereby hindering the progression of TMJOA. This is the first attempt to hinder TMJOA progression with FGF18, and has demonstrated the dual function of hydrogel in reducing inflammation levels and promoting cartilage repair in TMJOA environment. This discovery addresses the limitations of short retention time of FGF18 in clinical applications, and also provides a new strategy for improving articular cartilage repair by overcoming the inflammatory environment.

9 June 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JQJin Qiu
Jin Qiu
BHBingqiang Hua
Bingqiang Hua
XYXiaoping Ye
Xiaoping Ye
XLXianwen Liu
Xianwen Liu
Introduction: Kartogenin (KGN) is a small-molecule compound that has been reported to improve the chondrogenic differentiation of mesenchymal stem cells in vitro and to alleviate knee joint osteoarthritis in animal models. However, whether KGN has any effect on temporomandibular joint osteoarthritis (TMJOA) remains unclear.Methods: We first performed partial temporomandibular joint (TMJ) discectomy to induce TMJOA in rats. Histological analysis, tartrate-resistant acid phosphatase staining, and immunohistochemistry were used to assess the therapeutic effect of KGN on TMJOA in vivo. CCK8 and pellet cultures were used to determine whether KGN treatment could promote the proliferation and differentiation of FCSCs in vitro. Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to determine the expression of aggrecan, Col2a1, and Sox9 in FCSCs. Furthermore, we performed western blot to analysis the effect of KGN treatment on the expression of Sox9 and Runx2 in FCSCs.Results and discussion: Histological analysis, tartrate-resistant acid phosphatase staining, and immunohistochemistry showed that intra-articular injection of KGN attenuated cartilage degeneration and subchondral bone resorption in vivo. Further analyses of the underlying mechanisms revealed that KGN enhanced chondrocyte proliferation, increased the number of cells in both superficial and proliferative zones of TMJ condylar cartilage in vivo, enhanced the proliferation and chondrogenic differentiation of fibrocartilage stem cells (FCSCs), and upregulated the expression of chondrogenesis-related factors in vitro. Collectively, in our study, KGN was shown to promote FCSC chondrogenesis and restore TMJ cartilage, suggesting that KGN injections might be a potential treatment for TMJOA.

14 July 2026 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
YZYujin Zhao
Yujin Zhao
XLXianwen Liu
Xianwen Liu
Osteoarthritis (OA) is a common chronic degenerative joint disease characterized by progressive cartilage destruction, synovial inflammation, subchondral bone remodeling, and functional decline. Current treatments remain largely symptomatic and are unable to effectively halt or reverse disease progression. Increasing evidence indicates that epigenetic regulation provides a critical link between genetic susceptibility, mechanical loading, inflammation, aging, metabolic abnormalities, and pathological gene expression in OA. This review summarizes recent advances in OA epigenetics, with a particular focus on studies published over the past 2 years. We discuss classical mechanisms, including DNA methylation, histone modifications, and non-coding RNA-mediated regulation, and further highlight emerging epigenomic layers such as chromatin accessibility, enhancer and super-enhancer remodeling, three-dimensional genome organization, tissue-specific regulation, and the integration of genetics with single-cell and spatial multi-omics. These mechanisms contribute to inflammatory activation, chondrocyte metabolic imbalance, extracellular matrix degradation, programmed cell death, cellular senescence, oxidative stress, and abnormal inter-tissue crosstalk. Epigenetic biomarkers and epigenetic-based interventions, including extracellular vesicle-mediated delivery, engineered RNA therapeutics, and small-molecule epigenetic drugs, may offer new opportunities for early diagnosis, disease stratification, and precision therapy. However, current studies are limited by model heterogeneity, sample variability, insufficient causal validation, limited reproducibility, and translational challenges related to delivery and safety. Overall, epigenetic regulation provides a systematic framework for understanding OA heterogeneity and progression and may promote the development of disease-modifying therapeutic strategies.